Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

25.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.7K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

608
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
608
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

810
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
810
Pharmacovigilance01:19

Pharmacovigilance

934
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
934
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apadamtase Alfa: First Approval.

Drugs·2024
Same author

Zuranolone: First Approval.

Drugs·2023
Same author

Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa.

Drugs·2023
Same author

Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

Drugs·2023
Same author

Birch Bark Extract: A Review in Epidermolysis Bullosa.

Drugs·2023
Same author

Flotufolastat F 18: Diagnostic First Approval.

Molecular diagnosis & therapy·2023

Related Experiment Video

Updated: Aug 9, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Etranacogene Dezaparvovec: First Approval.

Young-A Heo1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 21, 2023
PubMed
Summary
This summary is machine-generated.

Etranacogene dezaparvovec, a gene therapy for haemophilia B, has gained FDA approval for adults with factor IX deficiency. This milestone offers a new treatment option for patients with serious bleeding episodes.

More Related Videos

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
07:43

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices

Published on: July 14, 2023

2.2K
Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

3.0K

Related Experiment Videos

Last Updated: Aug 9, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K
Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
07:43

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices

Published on: July 14, 2023

2.2K
Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

3.0K

Area of Science:

  • Gene therapy
  • Haematology
  • Viral vectors

Background:

  • Haemophilia B is a genetic bleeding disorder caused by a deficiency in factor IX (FIX).
  • Current treatments involve regular infusions of FIX concentrate, which can be burdensome.
  • Gene therapy offers a potential one-time treatment to address the underlying genetic cause.

Purpose of the Study:

  • To summarize the development milestones of etranacogene dezaparvovec.
  • To highlight the regulatory approvals for haemophilia B treatment.

Main Methods:

  • Review of etranacogene dezaparvovec development and clinical data.
  • Analysis of regulatory submission and approval processes in the USA and EU.

Main Results:

  • Etranacogene dezaparvovec (Hemgenix®) is an adeno-associated virus vector-based gene therapy.
  • Received US FDA approval in November 2022 for adults with haemophilia B.
  • Received positive opinion in the EU in December 2022 for haemophilia B.

Conclusions:

  • Etranacogene dezaparvovec represents a significant advancement in haemophilia B treatment.
  • This gene therapy provides a new therapeutic option for eligible adult patients.
  • The development and approval mark a key milestone in genetic medicine for bleeding disorders.